Literature DB >> 15065746

The course of depressive illness in general practice.

Frédéric Limosin1, Jean-Yves Loze, Myriam Zylberman-Bouhassira, Mark E Schmidt, Eléna Perrin, Frédéric Rouillon.   

Abstract

OBJECTIVE: Depression is reported to be common in primary care settings and to have a high likelihood of relapse during the 4- to 6-month period following initial symptomatic improvement. However, most prospective studies of long-term treatment of depression have been conducted with patients selected for participation in placebo-controlled drug protocols or psychiatric clinics associated with tertiary referral centres.
METHOD: We examined the treatment course and outcome of outpatients with major depressive episode treated in a primary care setting. The general practitioners were free to choose the treatment and its duration. Their only obligation was to assess the therapeutic outcome in terms of efficacy and safety and to perform a final evaluation at the end of the 6-month observation period or, if the patient was treated for a shorter period, at the end of the treatment.
RESULTS: Of the 476 patients involved, 308 (64.7%) responded to treatment and remained well, 117 (24.6%) showed no response, and 51 (10.7%) had an early relapse after initial improvement. Among the studied demographic, clinical, and therapeutic factors, the history of recurrent depression was the only variable with a significant effect size in predicting the course of the illness.
CONCLUSION: Patients with recurrent depression were at higher risk of relapse or nonresponse.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15065746     DOI: 10.1177/070674370404900207

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  8 in total

1.  Predictors of Poor Response to Depression Treatment in Primary Care.

Authors:  Rebecca C Rossom; Leif I Solberg; Gabriela Vazquez-Benitez; Robin R Whitebird; A Lauren Crain; Arne Beck; Jürgen Unützer
Journal:  Psychiatr Serv       Date:  2016-07-15       Impact factor: 3.084

2.  [Ambulatory care of patients with somatically unexplained complaints : A comparative qualitative study].

Authors:  S Döpfmer; M C Münchmeyer; T Natschke; W Herrmann; F Holzinger; R Burian; A Berghöfer; C Heintze
Journal:  Nervenarzt       Date:  2018-01       Impact factor: 1.214

Review 3.  The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence.

Authors:  James Lomas; Alexis Llewellyn; Marta Soares; Mark Simmonds; Kath Wright; Alison Eastwood; Stephen Palmer
Journal:  Pharmacoeconomics       Date:  2016-09       Impact factor: 4.981

4.  Risk factors for onset of multiple or long major depressive episodes versus single and short episodes.

Authors:  Bauke T Stegenga; Mirjam I Geerlings; Francisco Torres-González; Miguel Xavier; Igor Svab; Brenda W Penninx; Irwin Nazareth; Michael King
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-11-21       Impact factor: 4.328

Review 5.  Predictive effects of previous episodes on the risk of recurrence in depressive and bipolar disorders.

Authors:  Lars Vedel Kessing; Per Kragh Andersen
Journal:  Curr Psychiatry Rep       Date:  2005-12       Impact factor: 8.081

6.  Depression during the COVID-19 pandemic amongst residents of homeless shelters in France.

Authors:  Honor Scarlett; Camille Davisse-Paturet; Cécile Longchamps; Tarik El Aarbaoui; Cécile Allaire; Anne-Claire Colleville; Mary Convence-Arulthas; Lisa Crouzet; Simon Ducarroz; Maria Melchior
Journal:  J Affect Disord Rep       Date:  2021-09-27

Review 7.  Observational studies of depression in primary care: what do we know?

Authors:  Gail Gilchrist; Jane Gunn
Journal:  BMC Fam Pract       Date:  2007-05-11       Impact factor: 2.497

8.  Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium.

Authors:  Lieven Annemans; Mélanie Brignone; Sylvain Druais; Ann De Pauw; Aline Gauthier; Koen Demyttenaere
Journal:  Pharmacoeconomics       Date:  2014-05       Impact factor: 4.981

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.